This hypothesis is supported by the KEYNOTE-811 study, which demonstrated that pembrolizumab combined with trastuzumab and chemotherapy significantly improved survival in advanced HER-2-positive gastric or gastroesophageal junction adenocarcinoma patients (41). The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.